Product Description
A Peripherally Restricted mu-Opioid Receptor Antagonist (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31857840/)
Mechanisms of Action: OPR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Theravance Biopharma
Company Location: GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Company CEO: Rick E Winningham
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Constipation
Phase 1: Constipation|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ACTRN12614001152617 | P1 |
Completed |
Constipation |
2014-10-20 |
|
NCT01702194 | P1 |
Completed |
Constipation |
2013-02-01 |
22% |
NCT01655771 | P1 |
Completed |
Constipation |
2013-02-01 |
22% |
NCT01568411 | P1 |
Completed |
Healthy Volunteers |
2012-06-01 |
28% |